An insider just bought £63,965 of this FTSE 250 stock!

The new CFO of Dr Martens, the FTSE 250 icon, has just spent thousands buying the company’s shares. Should I also have the stock in my portfolio?

| More on:
Young black woman walking in Central London for shopping

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

On 30 May, the man in charge of the numbers at this FTSE 250 legend, purchased almost £64k of the company’s stock. Giles Wilson had only been in position at Dr Martens (LSE:DOCS) for three days before deciding to demonstrate his confidence in his new employer.

Such transactions always make me sit up and take notice.

As Peter Lynch, the American investor, once said: “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise“.

A good time to join?

However, since making its stock market debut in 2021, Dr Martens has issued five profits warnings. Wilson’s purchase suggests he’s confident there won’t be a sixth.

And I agree. That’s because on 16 May, the company issued the gloomiest of trading updates.

For the year ending 31 March 2025 (FY25), it said that under a “worst-case scenario”, its profit before tax could be around one-third of its FY24 level.

Although sales are down in all regions, the company’s struggling most in the US. During FY24, revenue in The Americas was 23.9% lower, than in FY23.

RegionFY23 (£m)FY24 (£m)Change (%)
Europe, Middle East and Africa443.0431.8-2.5
The Americas428.2325.8-23.9
Asia Pacific129.1119.5-7.4
Total1,000.3877.1-12.3
Source: company accounts

But I wonder if the company’s decided to be overly cautious in an attempt to avoid having to issue yet another profits warning. It sounded more optimistic when it said: “There are also scenarios where the profit outturn could be significantly better than this”.

Perhaps it’s a case of under-promising and over-delivering?

Doom and gloom

However, with both sales and earnings falling, its gross profit margin in decline and net debt rising, it’s hard to make a compelling investment case.

And there’s no guarantee that the company’s turnaround plan will work.

Also, income investors will be disappointed that the company recently slashed its dividend. Going forward, it hopes to return 35% of profits to shareholders. At the lower end of expectations, this could mean a payout of less than a penny a share.

Reasons to be optimistic

However, I remain positive about the company’s prospects. With its distinctive design and long heritage, the Dr Martens brand remains a valuable one. And the company claims brand recognition’s increasing in its key markets.

According to Straits Research, the global footwear market will be worth $568bn by 2031. With FY24 revenue of £1bn, there’s plenty of scope for the British icon to expand internationally. To do this, the company plans to spend heavily on marketing and promotional activities.

It also has a new chief executive, Ije Nwokorie, a former director at Apple, who will be keen to demonstrate his credentials.

But as tempted as I am to invest, I think I’m going to wait before reviewing the situation in a few months’ time. That’s because the company has historically performed better during the second half of its financial year.

The directors have warned that the first half of FY25 will see a fall of 20% in group revenue plus “cost headwinds”. It says earnings for the year will be “very second-half weighted”. If this proves to be correct, investors might not react when its results for the six months ended 30 September are published.

I’m therefore going to keep Dr Martens on my watchlist and take another look later in the year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Beard has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could this be one of the FTSE 100’s best cheap dividend shares?

Looking for the best dividend growth shares to buy? Our writer Royston Wild thinks this FTSE 100 housebuilder might well…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is this FTSE 100 passive income superstar also its best bargain right now?

This FTSE 100 gem still looks to me like one of the best bargains in the index. It appears very…

Read more »

Investing Articles

If I’d put £10,000 into Meta stock at the start of 2024, here’s what I’d have now

Our writer looks at the year-to-date performance of Meta stock and considers whether he'd consider buying this magnificent tech share.

Read more »

Hand arranging wood block stacking as step stair on paper pink background
Investing Articles

Investing £5 a day in this dividend giant can make me a £14,067 annual second income!

This FTSE 100 high-yield star can make me a major second income, supported by a strong business outlook and an…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Taylor Wimpey shares yield a fabulous 6.41%, but is the dividend safe?

Harvey Jones has enjoyed plenty of growth and income after buying Taylor Wimpey shares last year. But is today's high…

Read more »

Yellow number one sitting on blue background
Investing Articles

1 FTSE lithium stock I think could be ready to rocket

Jon Smith explains why the lithium price could be due a rally, and why shares of one related FTSE stock…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?

Jon Smith flags up a high-profile US stock that the great Warren Buffett bought back in 2020 but which has…

Read more »

White female supervisor working at an oil rig
Investing Articles

Could the UK general election be bad news for this FTSE 250 energy producer?

The country is due to vote in the general election on 4 July. Our writer looks at the possible implications…

Read more »